Nelfinavir (NFV) pharmacokinetics (PK) was evaluated in a cohort of HIV+/HCV+ pts with different degrees of liver impairment and compared to HIV+/HCV- controls. Group I included 21 HIV+/HCV+pts, while Group II was composed of 42 HIV+/HCV- subjects with normal ALT levels. NFV-PK was determined at steady state. Blood samples for PK analysis were obtained during a dosing interval (≥7 samples per patient). NFV and metabolite M8 plasma concentrations were determined simultaneously by a validated HPLC method.

HCV coinfection with normal or low grade ALT modifies nelfinavir disposition in HIV-positive patients / R., Maserati; P., Villani; M., Cusato; M. B., Regazzi; P., Zucchi; L., Sighinolfi; A., Catania; Guaraldi, Giovanni; C., Calzetti; D., Giacomazzi; L., Stoppini; M. C., Rossi; P., Castelli. - STAMPA. - not applicable:(2002), pp. 166-166. (Intervento presentato al convegno Sixth International Congress on Drug Therapy in HIV Infection tenutosi a Glasgow, UK nel 17- 21 November 2002).

HCV coinfection with normal or low grade ALT modifies nelfinavir disposition in HIV-positive patients

GUARALDI, Giovanni;
2002

Abstract

Nelfinavir (NFV) pharmacokinetics (PK) was evaluated in a cohort of HIV+/HCV+ pts with different degrees of liver impairment and compared to HIV+/HCV- controls. Group I included 21 HIV+/HCV+pts, while Group II was composed of 42 HIV+/HCV- subjects with normal ALT levels. NFV-PK was determined at steady state. Blood samples for PK analysis were obtained during a dosing interval (≥7 samples per patient). NFV and metabolite M8 plasma concentrations were determined simultaneously by a validated HPLC method.
2002
Sixth International Congress on Drug Therapy in HIV Infection
Glasgow, UK
17- 21 November 2002
R., Maserati; P., Villani; M., Cusato; M. B., Regazzi; P., Zucchi; L., Sighinolfi; A., Catania; Guaraldi, Giovanni; C., Calzetti; D., Giacomazzi; L., Stoppini; M. C., Rossi; P., Castelli
HCV coinfection with normal or low grade ALT modifies nelfinavir disposition in HIV-positive patients / R., Maserati; P., Villani; M., Cusato; M. B., Regazzi; P., Zucchi; L., Sighinolfi; A., Catania; Guaraldi, Giovanni; C., Calzetti; D., Giacomazzi; L., Stoppini; M. C., Rossi; P., Castelli. - STAMPA. - not applicable:(2002), pp. 166-166. (Intervento presentato al convegno Sixth International Congress on Drug Therapy in HIV Infection tenutosi a Glasgow, UK nel 17- 21 November 2002).
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/19358
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact